{"id":"inactivated-split-virion-influenza-virus","safety":{"commonSideEffects":[{"rate":"null","effect":"Pain, redness, or swelling at the injection site"},{"rate":"null","effect":"Fatigue"},{"rate":"null","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This inactivated, split-virion influenza virus vaccine works by exposing the body's immune system to a small, harmless piece of the influenza virus, prompting the body to produce antibodies that can fight the flu.","oneSentence":"Stimulates an immune response against influenza virus","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:35:57.666Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Influenza prevention"}]},"trialDetails":[{"nctId":"NCT05779020","phase":"PHASE3","title":"Immunogenicity and Safety of Butantan Quadrivalent Influenza Vaccine (Split Virion, Inactivated) in Infants and Children .","status":"COMPLETED","sponsor":"Butantan Institute","startDate":"2023-04-25","conditions":"Influenza, Human","enrollment":1373},{"nctId":"NCT04024228","phase":"PHASE3","title":"Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Europeans Adults 60 Years of Age and Older","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2019-10-28","conditions":"Influenza Immunization, Healthy Volunteers","enrollment":1539},{"nctId":"NCT03927131","phase":"PHASE3","title":"Safety and Immunogenicity of the Butantan Quadrivalent Influenza Vaccine","status":"COMPLETED","sponsor":"Butantan Institute","startDate":"2021-05-12","conditions":"Influenza, Human","enrollment":5822},{"nctId":"NCT03755427","phase":"PHASE2","title":"A Study of An Adjuvanted Inactivated H7N9 Influenza Vaccine","status":"COMPLETED","sponsor":"Shanghai Institute Of Biological Products","startDate":"2018-11-10","conditions":"H7N9 Influenza","enrollment":560},{"nctId":"NCT05895955","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of GPO Seasonal Tetravalent Inactivated Split Virion Influenza Vaccine in Healthy Thais","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mahidol University","startDate":"2023-11-04","conditions":"Influenza","enrollment":290},{"nctId":"NCT05431725","phase":"PHASE3","title":"Immunogenicity and Safety Study of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2022-07-18","conditions":"Seasonal Influenza","enrollment":2202},{"nctId":"NCT05642078","phase":"PHASE3","title":"Phase Ⅲ Clinical Study of Quadrivalent Influenza Virus Split Vaccine","status":"COMPLETED","sponsor":"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.","startDate":"2023-02-18","conditions":"Prevention of Influenza","enrollment":2550},{"nctId":"NCT04363359","phase":"PHASE2","title":"Clinical Trial of Quadrivalent Influenza Virus Split Vaccine","status":"COMPLETED","sponsor":"Shanghai Institute Of Biological Products","startDate":"2020-01-15","conditions":"Influenza","enrollment":1980},{"nctId":"NCT01551823","phase":"PHASE3","title":"The Clinical Trial Protocol for the Influenza Virus Vaccine (Split Virion, Inactivated) （Children Forms of Drug）","status":"COMPLETED","sponsor":"Institute of Medical Biology, Chinese Academy of Medical Sciences","startDate":"2012-03","conditions":"Influenza","enrollment":1200},{"nctId":"NCT01551810","phase":"PHASE3","title":"The Clinical Trial Protocol for the Influenza Virus Vaccine (Split Virion, Inactivated)","status":"COMPLETED","sponsor":"Institute of Medical Biology, Chinese Academy of Medical Sciences","startDate":"2012-03","conditions":"Influenza","enrollment":1200},{"nctId":"NCT05138705","phase":"PHASE4","title":"Clinical Trial of Quadrivalent Influenza Virus Split Vaccine in Population Aged 3-8 Years","status":"COMPLETED","sponsor":"Shanghai Institute Of Biological Products","startDate":"2021-12-14","conditions":"Influenza, Human","enrollment":380},{"nctId":"NCT04695717","phase":"PHASE3","title":"This Study Was Conducted to Evaluate the Safety and Immunogenicity of IVACFLU-S Produced in Children From 6 Months to Under 18 Years Old and the Elderly Over 60 Years Old in Vietnam","status":"COMPLETED","sponsor":"Vietnam Military Medical University","startDate":"2020-09-05","conditions":"Influenza","enrollment":864},{"nctId":"NCT03930017","phase":"","title":"Pregnancy, Arsenic and Immune Response","status":"COMPLETED","sponsor":"Johns Hopkins Bloomberg School of Public Health","startDate":"2018-10-14","conditions":"Arsenic--Toxicology, Immunologic Disorders Complicating Pregnancy, Vaccine Response Impaired","enrollment":784},{"nctId":"NCT04548518","phase":"PHASE3","title":"Immunogenicity and Safety of Tri Fluvac, a Seasonal Trivalent Inactivated Split Virion Influenza Vaccine, in Healthy Thai Elderly","status":"UNKNOWN","sponsor":"Mahidol University","startDate":"2020-08-03","conditions":"Influenza","enrollment":816},{"nctId":"NCT03300050","phase":"PHASE1","title":"Safety and Immunogenicity of a Live-attenuated Universal Flu Vaccine Followed by an Inactivated Universal Flu Vaccine","status":"COMPLETED","sponsor":"PATH","startDate":"2017-10-10","conditions":"Influenza, Vaccine","enrollment":65},{"nctId":"NCT03390166","phase":"PHASE2, PHASE3","title":"Immunogenicity and Safety of Tri Fluvac, a Seasonal Trivalent Inactivated Influenza Vaccine in Healthy Thai Adults","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2017-07-24","conditions":"Influenza","enrollment":945},{"nctId":"NCT02894840","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of GPO Seasonal Trivalent Inactivated Influenza Vaccine in Healthy Thai Adults","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2015-11","conditions":"Influenza","enrollment":340},{"nctId":"NCT01003288","phase":"NA","title":"Studies of Pandemic Influenza (H1N1) 2009 Vaccine in Bergen","status":"COMPLETED","sponsor":"University of Bergen","startDate":"2009-10","conditions":"Healthy","enrollment":255},{"nctId":"NCT01215669","phase":"PHASE4","title":"Study of Sanofi Pasteur's Intradermal Influenza Vaccine (IDflu™) in Adults and Elderly in Korea","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2010-10","conditions":"Influenza","enrollment":240},{"nctId":"NCT03016143","phase":"PHASE2","title":"Immunogenicity and Safety Study of Allantoic Split Inactivated Seasonal Influenza Vaccine (VSI)","status":"COMPLETED","sponsor":"Research Institute for Biological Safety Problems","startDate":"2016-10","conditions":"Influenza","enrollment":300},{"nctId":"NCT02545543","phase":"PHASE3","title":"A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 5 Through 17 Years of Age","status":"COMPLETED","sponsor":"Seqirus","startDate":"2015-09","conditions":"Influenza, Human","enrollment":2278},{"nctId":"NCT00735475","phase":"PHASE4","title":"A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine","status":"COMPLETED","sponsor":"Seqirus","startDate":"2008-10","conditions":"Influenza","enrollment":1268},{"nctId":"NCT00959049","phase":"PHASE3","title":"A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine in a Pediatric Population","status":"COMPLETED","sponsor":"Seqirus","startDate":"2009-09","conditions":"Influenza","enrollment":1474},{"nctId":"NCT00551031","phase":"PHASE2","title":"Study of Inactivated, Split-Virion Influenza Vaccine and Standard Fluzone® Vaccine in Adult and Elderly Subjects","status":"COMPLETED","sponsor":"Sanofi","startDate":"2007-10","conditions":"Influenza, Myxovirus Infection","enrollment":2098},{"nctId":"NCT00391053","phase":"PHASE3","title":"Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2006-10","conditions":"Orthomyxoviridae Infection, Influenza, Myxovirus Infection","enrollment":3851},{"nctId":"NCT00524940","phase":"PHASE2","title":"Trial to Describe the Safety and Immunogenicity of Fluzone®","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2007-08","conditions":"Influenza","enrollment":124},{"nctId":"NCT00772109","phase":"PHASE3","title":"Study of Fluzone Vaccine Administered by Intradermal Route in Comparison With Standard Fluzone® in Adults","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2008-10","conditions":"Orthomyxoviridae Infection, Influenza, Myxovirus Infection","enrollment":4292},{"nctId":"NCT01138397","phase":"PHASE3","title":"Immunogenicity and Safety of a Vaccine Against Influenza (2010-2011 Northern Hemisphere Season, Intradermal Route)","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2010-06","conditions":"Influenza","enrollment":129},{"nctId":"NCT01121822","phase":"PHASE3","title":"Immunogenicity and Safety of a Vaccine Against Influenza (2010-2011 Northern Hemisphere Season, Intramuscular Route)","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2010-05","conditions":"Influenza","enrollment":129},{"nctId":"NCT01032980","phase":"","title":"Post Authorization Safety Study of the Pandemic A/H1N1 Influenza Vaccines in Children and Adults","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2009-12","conditions":"Influenza, Swine-Origin A/H1N1 Influenza Virus","enrollment":3934},{"nctId":"NCT00776438","phase":"PHASE2","title":"Study of Immune Response in Adults and Elderly Subjects Vaccinated With Inactivated Influenza Vaccines","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2007-09","conditions":"Influenza, Orthomyxovirus Infections, Myxovirus Infection","enrollment":160},{"nctId":"NCT00718146","phase":"PHASE2","title":"Immunogenicity and Safety of the Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2008-2009 Formulation","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2008-06","conditions":"Influenza, Orthomyxoviridae Infections","enrollment":130},{"nctId":"NCT00343681","phase":"PHASE2","title":"A Study of the Immunogenicity and Safety of the 2006-2007 Influenza Vaccine","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2006-07","conditions":"Influenza, Orthomyxoviridae Infections","enrollment":120},{"nctId":"NCT00491257","phase":"PHASE2","title":"A Study of the Immunogenicity and Safety of the 2007-2008 Influenza Vaccine","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2007-06","conditions":"Influenza, Orthomyxoviridae Infections","enrollment":130},{"nctId":"NCT00946179","phase":"PHASE2","title":"Study of Influenza Vaccine (Split Virion, Inactivated) Northern Hemisphere 2009-2010 Formulation","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2009-05","conditions":"Influenza","enrollment":130},{"nctId":"NCT00491985","phase":"PHASE2","title":"Safety and Immunogenicity of 2 Formulations of an Intramuscular A/H5N1 Pandemic Influenza Vaccine in Children","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2007-06","conditions":"Influenza, Orthomyxoviridae Infections, Influenza A Virus Infection","enrollment":240},{"nctId":"NCT00383526","phase":"PHASE3","title":"Study of Inactivated, Split-Virion Influenza Vaccine Compared With the Reference Vaccine Vaxigrip® in the Elderly","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2006-09","conditions":"Orthomyxoviridae Infection, Influenza, Myxovirus Infection","enrollment":3707},{"nctId":"NCT00884182","phase":"PHASE2","title":"Safety and Immunogenicity of an Intramuscular A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine in Children","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2009-04","conditions":"Influenza, Orthomyxoviridae Infections, Orthomyxovirus Infections","enrollment":350},{"nctId":"NCT01053143","phase":"PHASE3","title":"Study of Swine-Origin A/H1N1 Influenza Non-Adjuvanted Vaccine in Healthy Adults in India","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2010-01","conditions":"Influenza, Pandemic Influenza, Influenza A Virus, H1N1 Subtype","enrollment":100},{"nctId":"NCT00956046","phase":"PHASE2","title":"A Study of Swine-origin A/H1N1 Influenza Vaccines in Healthy Europeans Children Aged 6 to 35 Months","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2009-09","conditions":"Influenza, Swine-origin A/H1N1 Influenza","enrollment":401},{"nctId":"NCT00296829","phase":"PHASE2","title":"Immunogenicity of Two Dosages of Inactivated, Split-Virion Influenza Vaccine Given by an Alternate Route in the Elderly","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2006-01","conditions":"Orthomyxoviridae Infection, Influenza, Myxovirus Infection","enrollment":1080},{"nctId":"NCT00415129","phase":"PHASE2","title":"Safety and Immunogenicity of an Intramuscular Pandemic Influenza Vaccine in Adults and the Elderly","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2006-06","conditions":"Influenza, Orthomyxoviridae Infections","enrollment":600},{"nctId":"NCT00945438","phase":"PHASE2","title":"Study of the Influenza Vaccine (Split Virion, Inactivated) Northern Hemisphere 2009-2010 Formulation (Intradermal Route)","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2009-05","conditions":"Influenza","enrollment":131},{"nctId":"NCT00545701","phase":"PHASE2","title":"Immunogenicity and Safety of an Intramuscular A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine in Adults","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2007-10","conditions":"Influenza, Orthomyxoviridae Infections","enrollment":100},{"nctId":"NCT00383539","phase":"PHASE3","title":"Lot-to-Lot Consistency Study of the Investigational, Inactivated, Split-Virion Influenza Vaccine in Adults","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2006-09","conditions":"Orthomyxoviridae Infection, Influenza, Myxovirus Infection","enrollment":2256},{"nctId":"NCT00606359","phase":"PHASE2","title":"Immunogenicity of the Inactivated Split-Virion Influenza Vaccine in Renal Transplant Subjects","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2007-11","conditions":"Influenza, Orthomyxoviridae Infections","enrollment":62},{"nctId":"NCT00457509","phase":"PHASE1","title":"Safety and Immunogenicity of H5N1 Adjuvanted, Inactivated, Split-Virion Pandemic Influenza Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2007-01","conditions":"Pandemic Influenza, Influenza A Virus Infection, Orthomyxoviridae Infections","enrollment":251},{"nctId":"NCT00258934","phase":"PHASE2","title":"Immunogenicity Study of the Influenza Vaccine in Adults","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2005-09","conditions":"Orthomyxoviridae Infections, Influenza","enrollment":978},{"nctId":"NCT00703651","phase":"PHASE2","title":"Study of Inactivated, Split-Virion Influenza Vaccine Administered by Intradermal Route Versus Vaxigrip® in Adults","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2003-09","conditions":"Influenza, Orthomyxoviridae Infection, Myxovirus Infection","enrollment":1150},{"nctId":"NCT00775450","phase":"PHASE2","title":"Influenza Vaccine Revaccination in Ambulatory Elderly Subjects","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2008-10","conditions":"Influenza, Orthomyxovirus Infection, Myxovirus Infection","enrollment":807},{"nctId":"NCT00934245","phase":"PHASE4","title":"Direct and Indirect Protection by Influenza Vaccine Given to Children in India","status":"COMPLETED","sponsor":"Wayne Sullender, M.D.","startDate":"2009-09","conditions":"Influenza","enrollment":4598},{"nctId":"NCT00845429","phase":"PHASE2","title":"Immunogenicity of a Split, Cell-Based, Inactivated, Trivalent Influenza Vaccine in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Sanofi","startDate":"2007-10","conditions":"Influenza, Orthomyxoviruses, Myxovirus Infection","enrollment":729},{"nctId":"NCT01511744","phase":"PHASE4","title":"Phase IV Clinical Trial of an Inactivated Influenza Split Vaccine","status":"COMPLETED","sponsor":"Hualan Biological Engineering, Inc.","startDate":"2011-11","conditions":"Human Influenza","enrollment":6000},{"nctId":"NCT01568788","phase":"NA","title":"Post-marketing Clinical Observation of an Inactivated Influenza Split Vaccine","status":"COMPLETED","sponsor":"Hualan Biological Engineering, Inc.","startDate":"2008-12","conditions":"Human Influenza","enrollment":600},{"nctId":"NCT00388583","phase":"PHASE2","title":"Study of Inactivated, Split-Virion Influenza Vaccine Compared With Standard Fluzone Vaccine in Elderly Subjects","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-09","conditions":"Orthomyxoviridae Infection, Influenza, Myxovirus Infection","enrollment":817},{"nctId":"NCT00664417","phase":"PHASE1","title":"Study of Different Formulations of an Intramuscular A/H5N1 Inactivated, Split Virion Influenza Adjuvanted Vaccine","status":"COMPLETED","sponsor":"Sanofi","startDate":"2008-04","conditions":"Influenza, Orthomyxoviridae Infections","enrollment":375},{"nctId":"NCT00192413","phase":"PHASE3","title":"Trial to Compare the Safety, Tolerability, and Efficacy of Influenza Virus Vaccine, (CAIV-T) With Inactivated, Influenza Vaccine, Trivalent, Types A & B, in Adults Aged 60 Years and Older Against Culture-confirmed Influenza","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2002-03","conditions":"Influenza","enrollment":3009},{"nctId":"NCT00391391","phase":"PHASE2","title":"Study of Inactivated, Split-Virion Influenza Vaccine Compared With Standard Fluzone Vaccine in Infants and Children","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-10","conditions":"Orthomyxoviridae Infection, Influenza, Myxovirus Infection","enrollment":520},{"nctId":"NCT01180621","phase":"PHASE2","title":"Evaluation of Seasonal Influenza Vaccine for 2010-2011 in Young Children","status":"COMPLETED","sponsor":"Dalhousie University","startDate":"2010-09","conditions":"Seasonal Influenza","enrollment":200},{"nctId":"NCT01055990","phase":"PHASE2","title":"Basic and Clinical Research on Applying Blood Fix to Treat Critical H1N1 Patients","status":"UNKNOWN","sponsor":"Shanghai Public Health Clinical Center","startDate":"2009-10","conditions":"Virus Diseases, Respiratory Tract Diseases, Respiratory Tract Infections","enrollment":7},{"nctId":"NCT00232947","phase":"PHASE3","title":"Study Comparing Immune Response to, and Safety of, Fluviral and Fluzone Influenza Vaccines in Persons 50 y.o. and Over","status":"COMPLETED","sponsor":"ID Biomedical Corporation, Quebec","startDate":"2005-10","conditions":"Influenza","enrollment":900}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":33,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Vaxigrip®","Fluzone®"],"phase":"phase_2","status":"active","brandName":"Inactivated, split-virion influenza virus","genericName":"Inactivated, split-virion influenza virus","companyName":"Sanofi Pasteur, a Sanofi Company","companyId":"sanofi","modality":"Biologic","firstApprovalDate":"","aiSummary":"Stimulates an immune response against influenza virus Used for Influenza prevention.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}